Department of Endocrinology, Diabetes& Metabolism, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, LE21 9QS, United Kingdom.
Department of Endocrinology, Diabetes& Metabolism, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, LE21 9QS, United Kingdom.
Mol Aspects Med. 2019 Apr;66:3-12. doi: 10.1016/j.mam.2018.10.004. Epub 2018 Nov 16.
The prevalence of "diabesity" - diabetes related to obesity - has increased tremendously over the past few decades because of the global obesity epidemic. Although bariatric surgery is the best treatment option for patients with diabesity, a majority of patients are managed only with antidiabetic drugs for various reasons. Diabetes control with antidiabetic agents may affect diabesity outcomes positively or negatively because of their effects on body weight and other metabolic parameters. For this reason, rational use of anti-diabetic medications is imperative to optimise long-term management of diabesity. Understanding the molecular mechanisms of antidiabetic drugs and/or drug combinations on diabesity outcomes are therefore important not only for the basic scientists but also for clinicians. This review explores the molecular signalling cascades of antidiabetic medications in the management of diabesity.
由于全球肥胖症的流行,过去几十年来,与肥胖相关的糖尿病(即“diabesity”)的患病率急剧上升。尽管减重手术是肥胖相关糖尿病患者的最佳治疗选择,但由于各种原因,大多数患者仅接受抗糖尿病药物治疗。由于抗糖尿病药物对体重和其他代谢参数的影响,糖尿病控制可能会对肥胖相关糖尿病的结果产生积极或消极的影响。出于这个原因,合理使用抗糖尿病药物对于优化肥胖相关糖尿病的长期管理至关重要。因此,了解抗糖尿病药物及其药物组合对肥胖相关糖尿病结果的分子机制不仅对基础科学家而且对临床医生都很重要。这篇综述探讨了抗糖尿病药物在肥胖相关糖尿病管理中的分子信号通路。